Antiretroviral treatment as prevention: Impact of the 'test and treat' strategy on the tuberculosis epidemic

Current HIV Research

Volumn 9, Issue 6, 2011, Pages 383-392

  Wood, Robin ^a,b,c   Lawn, Stephen D ^a,b,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Communicable disease control; HAART; highly active antiretroviral therapy; HIV prevention; tuberculosis prevention

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

AFRICA; ARTICLE; BACTERIAL TRANSMISSION; CD4 LYMPHOCYTE COUNT; CONTACT EXAMINATION; DISEASE ASSOCIATION; EARLY INTERVENTION; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; SHORT COURSE THERAPY; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; TUBERCULOSIS, PULMONARY;

EID: 80055119084     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798038524     Document Type: Article

References (78)

1. Tuberculosis--United States, 1985 and the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep 1986; 35(5): 74-6.
2. Rieder HL, Cauthen GM, Comstock GW, Snider DE, Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989; 11: 79-98.
3. Raviglione MC, Snider DE, Jr., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273(3): 220-6.
4. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug- resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326(23): 1514-21.
5. Kaye K, Frieden TR. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev 1996; 18(1): 52-63.
6. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4(4): 325-33.
7. World Health Organization. Global tuberculosis control - epidemiology, strategy, financing. World Health Organization, Geneva 2009. WHO/HTM/TB/2009.411. Available at: http://www.who.int/tb/publications/global_report/2009/en/index.html. Accessed July 26, 2011.
8. Lawn SD, Bekker L-G, Middelkoop K, Myer L, Wood R. Impact of HIV on age-specific tuberculosis notification rates in a peri- urban community in South Africa. Clin Inf Dis 2006; 42: 1040-7.
9. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375(9729): 1906-19.
10. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-64.
11. Lawn SD, Kranzer K, Wood R. Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited Settings. Clin Chest Med 2009; 30: 685-99.
12. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57.
13. Reider HL. Epidemiological basis of tuberculosis control. Paris: International Union against Tuberculosis and Lung Disease 1999.
14. Vynnycky E, Fine PEM. Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int J Epi 1999; 28: 327-34.
15. Middelkoop K, Bekker LG, Myer L, Dawson R, Wood R. Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin Infect Dis 2008; 47: 349-55.
16. Shanaube K, Sismanidis C, Ayles H, et al. Annual Risk of Tuberculous Infection Using Different Methods in Communities with a High Prevalence of TB and HIV in Zambia and South Africa. PLoS ONE 2009; 4(11): e7749. doi:10.1371/journal.pone.
17. Wood R, Liang H, Wu H, et al. Changing prevalence of TB infection with increasing age in high TB burden townships in South Africa. Int J Tuberc Lung Dis 2010; 14: 406-12.
18. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326(4): 231-5.
19. Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J R Soc Interface 2007; 4(14): 523-531.
20. Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10: 489-98.
21. Wood R, Middelkoop K, Myer L, et al. The burden of undiagnosed tuberculosis in an African community with high HIV-prevalence: implications for TB control. Am J Resp Crit Care Med 2007; 175(1): 87-93.
22. Dubos R, Dubos J. The White Plague: Tuberculosis, Man, and Society. Boston: Little, Brown and Company 1952.
23. Abbey H. An examination of the Reed-Frost theory of epidemics. Hum Biol 1952; 24: 201-33.
24. Wood R, Lawn SD, Johnstone-Robertson S, Bekker L-G. Tuberculosis control has failed in South Africa: time to reappraise strategy. S Afr Med J 2011; 101(2): 111-4.
25. AIDS epidemic update: November 2009. UNAIDS, Geneva 2009. Available at: http://www.unaids.org/en/dataanalysis/epidemiology/2009aidsepid emicupdate/. Accessed July 26, 2011.
26. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57: 275-99.
27. Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005; 9(11): 1183-203.
28. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-79.
29. Rana F, Hawken MP, Meme HK, et al. Autopsy findings in HIV-1- infected adults in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 83-5.
30. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6: 55-63.
31. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV infected patients treated for tuberculosis in Abidjan, Cote d'Ivoire. AIDS 1995; 9: 1251-4.
32. Abdool Karim SS, Churchyard G, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374: 921-33.
33. Wood R. Integrating the Treatment of HIV and TB in Developing Countries. Therapy 2007; 4(6): 787-96.
34. Coetzee D, Hilderbrand K, Goemaere E, Matthys F, Boelaert M. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health 2004; 9(6): A11-5.
35. Lawn SD, Fraenzel A, Kranzer K, Caldwell J, Bekker L-G, Wood R. Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S Afr Med J 2011; 101(4): 258-62.
36. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527-33.
37. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pre-treatment screening strategy. AIDS 2010; 24: 1323-8.
38. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening prior to antiretroviral therapy: diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23: 1875-80.
39. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-12.
40. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19: 1113-24.
41. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-6.
42. Wendland T, Furrer H, Vernazza PL, et al. HAART in HIV- infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999; 13: 1857-62.
43. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13: 177-84.
44. Kampmann B, Tena-Coki GN, Nicol MP, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV- infected children receiving HAART. AIDS 2006; 20: 1011-8.
45. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4(11): 1026-31.
46. Girardi E, Sabin CA, d'Arminio MA, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41(12): 1772-82.
47. Muga R, Ferreros I, Langohr K, et al. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS 2007; 21(18): 2521-7.
48. Moreno S, Jarrin I, Iribarren JA, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis 2008; 12(12): 1393-400.
49. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2007; 2(9): e826.
50. Santoro-Lopes G, de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34(4): 543-6.
51. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21(11):1441-8.
52. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23(5): 631-6.
53. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009; 30(4): 685-99.
54. th Union World Conference on Lung Health, 2009 December 3-7; Cancun, Mexico. Special symposium.
55. Girardi E, Sabin CA, d'Arminio MA, et al. Incidence of Tuberculosis among HIVinfected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-82.
56. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-16.
57. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-25.
58. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191(2): 150-8.
59. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345(8950): 607-10.
60. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-52.
61. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175(11): 1199-206.
62. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV- associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190(9): 1670-6.
63. Haar CH, Cobelens FG, Kalisvaart NA, et al. HIV-related mortality among tuberculosis patients in The Netherlands, 1993-2001. Int J Tuberc Lung Dis 2007; 11(9):1038-41.
64. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50(2): 148-52.
65. Varma JK, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 2009; 9: 42.
66. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43(1): 42-6.
67. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13(7): 1001-7.
68. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. World Health Organization, Geneva 2010. Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed July 26, 2011.
69. Lawn SD, Myer L, Orrel C, Bekker L-G, Wood R. Early mortality among patients accessing a community -based antiretroviral service in South Africa: Implications for program design. AIDS 2005; 19: 2141-8.
70. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-908.
71. Bacaer N, Oufliki R, Pretorius C, Wood R, Williams B. Modeling the joint epidemics of TB and HIV in a South African township. Journal of Mathematical Biology 2008; 57(4): 557-93.
72. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-7.
73. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R. Will ART do it? Antiretroviral therapy for control of HIV-associated tuberculosis. Int J Tuberc Lung Dis 2010; submitted.
74. Middelkoop K, Bekker L-G, Morrow C, Zwane E, Wood R. Childhood tuberculosis infection and disease in a South African township: a spatial and temporal transmission analysis. S Afr Med J 2010; 99(10): 738-43.
75. Pacheco AG, Durovni B, Cavalcante SC, et al. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS ONE 2008; 3: e3132.
76. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2008; 1 2(7): 769-772.
77. Middelkoop K, Bekker L-G, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Resp Crit Care Med 2010; 182: 1080-5.
78. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368: 531-6.